A transplant that no longer forces a trade-off

For decades, doctors treating blood cancer patients with stem cell transplants have faced an uncomfortable math problem. Kill the cancer, but risk the donor's immune cells turning on the patient's own body afterward. That complication, chronic graft-versus-host disease, has quietly limited how aggressively physicians could offer a treatment that is otherwise curative for leukemias and related cancers. On July 1, 2026, the FDA approved a therapy designed to break that trade-off apart.

The drug is called Tregzi, developed by Orca Bio and known in clinical circles by its earlier name, Orca-T. It is the first regulatory T cell-based immunotherapy ever approved for patients with blood cancers undergoing allogeneic hematopoietic stem cell transplantation, according to the FDA's own announcement. Karim Mikhail, acting director of the FDA's Center for Biologics Evaluation and Research, called chronic GVHD "one of the most feared and difficult-to-prevent complications" for transplant patients, and said the approval reflects what precision cellular therapy can now deliver.

What actually goes into the syringe

Tregzi isn't a single drug in the conventional sense. It's a personalized, three-part cellular product manufactured individually for each patient using cells drawn from an 8/8 HLA-matched donor's peripheral blood. The formula combines hematopoietic stem and progenitor cells, which rebuild the patient's blood and immune system after chemotherapy; highly purified regulatory T cells, which are meant to suppress the donor immune response that causes GVHD; and conventional T cells, which preserve the graft-versus-leukemia effect that helps prevent cancer relapse.

That last detail matters more than it might seem. Historically, efforts to reduce GVHD risk by stripping T cells from a donor graft have sometimes weakened the transplant's ability to fight off remaining cancer cells. Tregzi's design tries to have it both ways — dial down the harmful immune reaction while keeping the beneficial one intact. Robert Negrin of Stanford Medicine, who worked on the therapy's foundational research, called the approval "a defining moment for the transplant community" in comments distributed by Orca Bio.

The trial numbers behind the approval

The FDA based its decision on the Phase 3 PRECISION-T trial, a randomized, open-label study spanning 19 treatment centers and enrolling 187 adult patients with acute myeloid leukemia, acute lymphoblastic leukemia, myelodysplastic syndrome, and mixed-phenotype acute leukemia. Patients were randomized to receive either Tregzi plus single-agent tacrolimus, or a standard allogeneic transplant with a combination of tacrolimus and methotrexate.

The results were not marginal. At one year, 78% of Tregzi recipients were alive and free of chronic GVHD, compared to 38.4% of patients who received a standard transplant, according to trial data reported by BioPharm International and confirmed in Orca Bio's own release. After accounting for death as a competing risk, moderate-to-severe chronic GVHD occurred in just 12.6% of Tregzi patients versus 44% in the control group. Overall survival came in at 94% for the Tregzi arm compared to 83% for standard transplant recipients, according to reporting from Fierce Pharma. No cases of graft failure were reported in either arm, and severe infusion reactions were absent entirely.

Fewer infections, not just less GVHD

One secondary finding deserves more attention than it's gotten. Grade 3 or higher infections — a major driver of death and hospitalization after transplant — occurred in an estimated 44% of Tregzi patients at one year, compared to 51% in the control group, according to data cited by CGTlive. That's a meaningful gap for a population where infection risk is already elevated by immunosuppression. It suggests Tregzi's engineered immune reconstitution isn't just suppressing GVHD symptoms; it may be helping patients' immune systems rebuild in a more functional, balanced way overall.

Acute GVHD data told a similar story. The cumulative incidence of Grade 3 or 4 acute GVHD at day 180 was 6% with Tregzi versus 10% with standard transplant, a difference researchers described as statistically significant. Taken together, these numbers point toward a therapy that improves the transplant experience broadly, not just one narrow complication.

The price tag, and what happens next

Orca Bio has set the wholesale acquisition cost for Tregzi at $428,000, according to BioSpace reporting on the approval. That figure will draw scrutiny given the therapy's individualized manufacturing process, which requires apheresis coordination and centralized cell-processing infrastructure at each transplant center that offers it — a logistical lift that BioPharm International flagged as a real implementation hurdle, not just a financial one.

The FDA granted Tregzi both orphan drug and regenerative medicine advanced therapy designations during its review, signals that regulators saw the therapy addressing a serious unmet need. For patients facing a leukemia diagnosis and the prospect of a transplant, that unmet need was never abstract — chronic GVHD has long meant trading a cancer cure for years of skin, lung, liver, or eye complications. Tregzi doesn't eliminate that risk. But cutting it by more than two-thirds, while apparently preserving the transplant's cancer-fighting power, is the kind of result that changes how oncologists will frame the conversation with patients weighing whether to proceed.

*This article was researched using publicly available reporting from the FDA, Orca Bio, BioPharm International, Fierce Pharma, BioSpace, CGTlive, and Oncology Nursing News. It is intended for informational purposes and is not medical advice.*